Michael Ackerman (Genetic Cardiologist, Mayo Clinic, Rochester, MN, USA) discusses the avoidance of implantable cardioverter-defibrillator implantation in primary electrical disease and how this might be achieved in practice.
Questions:
1. How can we avoid implantable cardioverter-defibrillator (ICD) implantation in primary electrical disease? (0:09)
Disclosures: Michael Ackerman is a consultant for Audentes Therapeutics, Boston Scientific, Gilead Sciences, Invitae, Medtronic, MyoKardia and St Jude Medical, and receives equity/royalties from AliveCor, Blue Ox Health and StemoniX.
Filmed in partnership with Arrhythmia Alliance.
